Tags: Cancer | brain | cancer | drug | VBL-111 | treatment | Avastin

Brain Cancer Drug Shows Effectiveness in Trial

Wednesday, 25 March 2015 12:35 PM


Israel-based VBL Therapeutics said a mid-stage study of its experimental brain cancer drug met the main goal of increasing overall survival.
 
The drug developer's shares were up 20 percent at $6.70 in premarket trade on Wednesday.
The company said its drug, VBL-111, significantly improved overall survival when used in combination with Roche AG's cancer treatment, Avastin.
 
The company said it stopped testing the drug as a monotherapy after the disease progressed in nearly half the patients in the study who were given only VBL-111.
 
VBL is also testing VBL-111 as a treatment for thyroid cancer and ovarian cancer.

© 2020 Thomson/Reuters. All rights reserved.


   
1Like our page
2Share
Health-News
Israel-based VBL Therapeutics said a mid-stage study of its experimental brain cancer drug met the main goal of increasing overall survival. The drug developer's shares were up 20 percent at $6.70 in premarket trade on Wednesday.The company said its drug, VBL-111,...
brain, cancer, drug, VBL-111, treatment, Avastin
98
2015-35-25
Wednesday, 25 March 2015 12:35 PM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved